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Abstract. Auranofin, (AF), a gold(I) complex in clinical use for the 
therapy of rheumatoid arthritis, is reported here to produce remarkable 
bactericidal effects in vitro against Staphylococcus sp. Noticeably, a 
similar antimicrobial action and potency are also noticed toward a few 
MRSA strains but not toward E. Coli. The time and concentration 
dependencies of the antimicrobial actions of AF have been  characterized 
through recording time kill curves, and a concentration dependent profile 
highlighted. Overall, the present  results point out  that auranofin might be 
quickly and successfully repurposed for the treatment of severe bacterial 
infections due to resistant Staphylococci. 
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Introduction 
 Drug discovery and development is nowadays a very expensive, 
time-consuming, and risky process as witnessed by the limited 
number of new drugs approved every year. Attrition rates are 
extremely high, even during the late phases of clinical evaluation, 
with a huge financial impact. To speed up drug discovery and 
development and reduce failure rates and the associated costs, drug 
repositioning or repurposing may be considered as a highly effective 
and promising strategy (Chong et al. 2007,  Aroson 2007).   
Drug repositioning involves the investigation of drugs that were 
already approved for the treatment of other diseases and/or whose 
mechanisms or targets are known. Various methods including new 
screening platforms and advanced in silico and bioinformatic 
approaches may be exploited for the identification of the best 
candidates for drug repositioning. A few successful stories of drug 
repositioning are well documented in the recent literature such as 
those of finasteride, thalidomide, sildenafil and metformin (Cavalla 
2013).  
Auranofin, AF (I), is a mixed ligand gold compound in clinical 
use since 1985 for the treatment of severe rheumatoid arthritis 
(Ridaura) (Shaw 1999). It consists of a gold(I) center linearly 
coordinated to a triethylphosphine and a thiosugar ligand as shown in 
figure 1. 
 
 
 
 
Figure 1. Chemical Structure of Auranofin 
The presence of the strong phosphine ligand confers favourable 
pharmacological properties to this gold(I) center while the thiosugar 
ligand is a somewhat weaker ligand and may be released more easily. 
Following the release of the thiosugar, a coordination position is 
made available for gold(I) binding to biomolecules (Zou et al. 2000).  
The development of AF as an antiarthritic drug was inspired by 
the traditional use of various gold compounds in the treatment of this 
disease dating back to the 1930s’. In comparison to other established 
antiarthritic gold compounds, AF has the big advantage of being 
administered orally. Yet, in spite of numerous investigations carried 
out so far, the actual mechanisms through which AF produces its 
favourable effects in RA are still unclear and largely unknown. There 
is just some limited evidence that AF can modulate the immune 
response and affect inflammation’s mediators (Bondenson 1997, 
Messori et al 2004, Han et al. 2008). 
Remarkably, auranofin combines the conspicuous affinity (after 
activation) of the gold(I) center for various “soft” donors (in 
particular S and N donors from proteins’ side chains), with a 
moderate and largely acceptable systemic toxicity. This paves the 
way to its repositioning for new and different therapeutic uses. While 
the drug repositioning strategy has been extensively applied to 
several organic drugs, very limited examples still concern the case of  
inorganic drugs. Nevertheless, in recent years, a number of new 
attractive pharmaceutical actions were disclosed for AF including 
promising anticancer, antiviral and antiprotozoan properties;. in 
particular AF seems to be very effective for the treatment of of 
Schistosoma and also of Plasmodium falciparum infections (Shaw 
1999, Kuntz 2007, Sanella et al. 2008). The state of art on the new 
medical uses of AF is described in detail in a comprehensive review 
article (Madeira et al. 2012).  
Specifically, we wondered whether auranofin might possess 
effective antibacterial properties toward microorganisms that are 
difficult to treat with the available drugs and antibiotics. This is now 
a very urgent and unmet medical need as the number of innovative 
clinically approved antibiotics has dramatically decreased during the 
last two decades while an increasing number of multi resistant and 
highly dangerous bacteria (the so called superbugs) has appeared. 
Quite surprisingly, no systematic study exists in the literature on the 
antibacterial uses of AF; just some  fragmentary observations are 
available (Novelli et al. 1999).  
However, very recently, AF has been reported to be highly 
effective toward Clostridium difficile (Jackson-Rosario Self 2010), 
Treponema denticola (Jackson-Rosario Self 2009), and 
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metronidazole-resistant Giardia lamblia (Tejman-Yarden et al. 
2013) .      
The above arguments led us to explore in more depth the 
antimicrobial properties of auranofin toward a few representative 
bacterial strains. 
 
Materials and methods 
 
Strains, antibiotics, and media 
 
The strains used for the experiments were Escherichia coli ATCC 
25922, Staphylococcus aureus ATCC 25923, Staphylococcus aureus 
USA 300, Staphylococcus epidermidis ATCC 12228, Staphylococcus 
epidermidis ATCC 35984 (biofilm producer) and 5 recent clinical 
isolates of methicillin-resistant Staphylococcus aureus (MRSA). 
Fresh dilutions of auranofin were prepared daily. 
The in vitro experiments were performed in Mueller Hinton broth and 
Mueller Hinton agar (Oxoid, UK). 
 
MIC determination 
 
Minimal inhibitory concentrations (MIC) were determined according 
to the Clinical and Laboratory Standards Institute (CLSI) guidelines 
and using a broth dilution method. Briefly, two-fold broth serial 
dilutions were performed at inoculum sizes of 1x106 CFU/ml 
obtained from a 18-24h incubation at 35°C. Incubation of test tubes, 
containing a final volume of 1 ml, was done at 35°C for 18h-24h. The 
MIC was defined as the lowest concentration of antimicrobial agent 
that inhibits the development of visible growth in the tubes (Clinical 
Laboratory Standards Institute 2004). 
  
Time-kill curves 
 
The killing activity of auranofin (I) and of its analogue (II) over time 
was evaluated in liquid medium (Mueller–Hinton Broth) at 37°C 
while shaking. The activity was examined against S. aureus ATCC 
25923 at a final concentration of between 106 colony forming units 
(CFU)/mL and 107 CFU/mL in either the presence or absence of 
auranofin (I) or derivative (II)  at concentrations of 1/4xMIC, MIC, 
2xMIC, 4xMIC, 16xMIC and 64xMIC. Bacterial growth was 
evaluated at time zero (before the addition of the two complexes) and 
at 1h, 2h, 4h, 6h and 24h after addition of treatment agents, both in 
the control and antibiotic samples, using the CFU/mL count method. 
At each hour, 0.1mL of the sample removed from the bottles were 
diluted two-fold with normal saline (0.9% NaCl) and spread on 
Mueller-Hinton agar plates using L-shaped rod and incubated for 24h 
at 37°C. Colony count of bacteria between 30–300 CFU/mL for each 
plate was determined to obtain time-kill curves (Clinical Laboratory 
Standards Institute 2004). 
 
Results and discussion 
 
 AF was tested against two reference strains, namely Escherichia 
coli ATCC 25922 and Staphylococcus aureus ATCC 25923 that are 
representative of Gram negative and Gram positive bacteria, 
respectively. For comparison purposes parallel experiments were 
carried out on AuClPEt3 (II) an auranofin analogue where the 
thiosugar ligand is replaced by a chloride ligand (Shaw 1999). 
The in vitro antimicrobial properties of both auranofin and its 
analogue were assessed by determination of the minimal inhibitory 
concentration (MIC) and by time-kill analysis. The high MIC values 
observed with both gold compounds in the case of E. coli ATCC 
25922 strain (>8mg/l) point out that both compounds are practically 
ineffective against Enterobacteriaceae. In contrast, both compounds 
are characterized by a remarkable in vitro activity with low MIC 
values (ranging from 0.125 to 0.5 mg/l) against the  S. aureus ATCC 
25923 strain (Table 1). 
 
 
Auranofin 
(mg/l) 
AuClP(Et)3 
(mg/l) 
E. coli ATCC 25922  > 8 > 8 
S. aureus ATCC 25923 0.25 - 0.5 0.125 – 0.25 
S. aureus USA 300 0.25 0.125 
S. aureus MRSA 1 0.25 0.125 
S. aureus MRSA 2 0.25 0.125 
S. aureus MRSA 3 0.25 0.125 
S. aureus MRSA 5 0.125 – 0.25 0.125 
S. aureus MRSA 6 0.25 0.125 
S. epidermidis ATCC 12228 0.25 0.125 
S. epidermidis ATCC 35984 
(biofilm producer) 
0.25 0.125 
Tab 1. MIC values for the two gold complexes Auranofin and AuClP(Et)3 against 
different bacteria strains (range from 4 experiments). 
These observations prompted us to analyse in more detail the in 
vitro activity of I and II against different reference strains of the 
Staphylococcus genus including S. epidermidis and methycillin 
resistant S. aureus (MRSA) and also against recent clinical isolates of 
MRSA; indeed, this latter pathogen, causing extensive morbidity and 
mortality is considered worldwide as a very difficult one to treat and 
eradicate(Karampela et al. 2012). Interestingly, both gold compounds 
turned out to be very active in vitro against all tested strains, 
including all clinical isolates independently of being methycillin 
sensitive or resistant and biofilm producer or not. Typically, the 
resulting MIC values ranged from 0.125 to 0.5 mg/l and from 0.125 
to 0.25mg/l, for compound I or II, respectively, with no significant 
differences on their in vitro antimicrobial potency (Table 1). 
 Time kill curves offer reliable and detailed information on the 
mode through which antimicrobial agents cause bacteria’s death. The 
results obtained with the time–kill analysis in the case of I and II are 
shown in fig 2 and 3. Notably, such a  method  may give specific 
insight on the pharmaco-dynamic properties of the different drugs 
regarding either their  concentration- or time-dependent activity 
(Craig 1998).  
 
Figure 2. Killing curves with Auranofin against S. aureus ATCC 25923 (mean of 
two experiments) 
 Figure 3. Killing curves with derivative (II) against S. aureus ATCC 25923 (mean 
of two experiments). 
 Analysis of the obtained killing curves indicates that the 
antibacterial activities of both auranofin and its analogue II on the S. 
aureus ATCC 25923 strain (with a MIC of 0.5 mg/L and 0.125 for I 
and II respectively) are very pronounced. Auranofin showed  
inhibition of bacterial growth for 12 h at MIC and for 24 h at 2×MIC, 
whereas no re-growth was observed even after 24 h at 16 and 
64×MIC (fig. 2). Compound II showed a somewhat lower 
antibacterial profile with inhibition of bacterial growth for 8 h at 
4xMIC, though no regrowth was observed after 24 h at 16 and 
64×MIC (fig. 3). Auranofin demonstrated a concentration-dependent 
bactericidal activity with sterilization at 6–12 h at concentrations 
>4×MIC,  with a reduction in the bacterial count of 3 log compared to 
the control in the first 6 h (fig. 2). 
Owing to this data, complexes I and II may be classified as 
strong antimicrobial agents versus S. aureus and S. epidermidis 
strains. Their antimicrobial properties are very similar both in terms 
of potency and of the spectrum of sensitive strains. As complexes I 
and II only differ in the nature of the more labile ligand (the 
tetracetylthioglucose ligand in I and chloride in II) it is 
straightforward to assume that such ligand just plays an ancillary role 
in the overall antimicrobial activity while the triethylphosphine 
ligand constitutes an important part of the pharmacophore. The 
detailed mode of bacteria growth inhibition caused by these gold 
compounds will  be the subject of further  mechanistic studies; on the 
basis of existing literature, we can just state that there are two 
plausible mechanisms that warrant specific investigation, namely 
interference with selenium metabolism and inhibition of thioredoxin 
reductase and related enzymes (Jackson-Rosario Self 2009). 
Overall, in view  of the here reported  in vitro results, it is evident 
that the clinically established antiarthritic drug auranofin 
demonstrates a high bactericidal activity against Staphylococcus sp; a 
similar antimicrobial potency is manifested versus the MRSA strains. 
Based on a preliminary set of experiments, the activity of  auranofin 
appears to be characterized by a concentration-dependent character. 
These observations imply that AF is a promising agent that might be 
repurposed for the treatment of severe bacterial infections due to 
resistant Staphylococci; further investigations in animal models are 
needed. On the other hand, studies will be deepened to understand the 
effective molecular mechanisms through which auranofin manifests 
its potent antibacterial properties and to elucidate the reasons for the 
large differences in sensitivity between S. aureus and E. coli. 
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